Holen Sie sich die Stockscreener-App
397.55
3.65%
-15.08
Schlusskurs vom Vortag:
$412.63
Offen:
$408.86
24-Stunden-Volumen:
1.61M
Relative Volume:
1.49
Marktkapitalisierung:
$52.52B
Einnahmen:
$3.21B
Nettoeinkommen (Verlust:
$43.57M
KGV:
1,653.01
EPS:
0.2405
Netto-Cashflow:
$221.36M
1W Leistung:
-13.22%
1M Leistung:
-12.19%
6M Leistung:
+30.49%
1J Leistung:
+62.09%
1-Tages-Spanne:
$387.03
$410.04
1-Wochen-Bereich:
$387.03
$449.78
52-Wochen-Spanne:
$205.87
$495.55
Alnylam Pharmaceuticals Inc Stock (ALNY) Company Profile
Firmenname
Alnylam Pharmaceuticals Inc
Sektor
Branche
Telefon
(617) 551-8200
Adresse
675 WEST KENDALL STREET, CAMBRIDGE, MA
Vergleichen Sie ALNY mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ALNY
Alnylam Pharmaceuticals Inc
|
397.55 | 54.51B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.04 | 113.14B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
741.29 | 78.49B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
877.94 | 54.76B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
197.01 | 41.64B | 447.02M | -1.18B | -906.14M | -6.1812 |
Alnylam Pharmaceuticals Inc Stock (ALNY) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-08-04 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2025-08-04 | Hochstufung | Wolfe Research | Underperform → Peer Perform |
| 2025-07-30 | Fortgesetzt | Raymond James | Outperform |
| 2025-07-21 | Eingeleitet | Truist | Buy |
| 2025-03-31 | Eingeleitet | Redburn Atlantic | Buy |
| 2025-03-24 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2024-11-12 | Herabstufung | Wolfe Research | Peer Perform → Underperform |
| 2024-10-16 | Eingeleitet | Scotiabank | Sector Outperform |
| 2024-08-16 | Hochstufung | Goldman | Neutral → Buy |
| 2024-02-16 | Herabstufung | Goldman | Buy → Neutral |
| 2024-02-15 | Eingeleitet | Wolfe Research | Peer Perform |
| 2023-12-08 | Eingeleitet | Wells Fargo | Equal Weight |
| 2023-10-11 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2023-09-29 | Eingeleitet | Raymond James | Outperform |
| 2023-05-05 | Hochstufung | BMO Capital Markets | Market Perform → Outperform |
| 2023-04-26 | Eingeleitet | SMBC Nikko | Neutral |
| 2023-03-21 | Eingeleitet | Bernstein | Outperform |
| 2023-01-18 | Eingeleitet | Canaccord Genuity | Buy |
| 2022-09-09 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2022-07-13 | Eingeleitet | Cantor Fitzgerald | Neutral |
| 2022-06-27 | Herabstufung | Guggenheim | Buy → Neutral |
| 2022-06-07 | Eingeleitet | William Blair | Outperform |
| 2022-04-25 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2022-03-01 | Eingeleitet | Citigroup | Buy |
| 2022-02-03 | Hochstufung | Guggenheim | Neutral → Buy |
| 2022-01-03 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2021-11-22 | Hochstufung | Goldman | Neutral → Buy |
| 2021-11-22 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2021-11-01 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2021-10-04 | Hochstufung | UBS | Neutral → Buy |
| 2021-08-04 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2021-02-22 | Herabstufung | Guggenheim | Buy → Neutral |
| 2021-02-12 | Herabstufung | Citigroup | Buy → Neutral |
| 2021-02-12 | Bestätigt | H.C. Wainwright | Buy |
| 2021-01-25 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
| 2020-09-30 | Fortgesetzt | Berenberg | Hold |
| 2020-09-08 | Eingeleitet | Citigroup | Buy |
| 2020-08-11 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2020-05-13 | Eingeleitet | RBC Capital Mkts | Sector Perform |
| 2020-05-07 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2020-04-24 | Fortgesetzt | Evercore ISI | Outperform |
| 2020-03-19 | Eingeleitet | Berenberg | Buy |
| 2019-12-19 | Bestätigt | Chardan Capital Markets | Buy |
| 2019-11-20 | Eingeleitet | Oppenheimer | Outperform |
| 2019-11-13 | Eingeleitet | BofA/Merrill | Buy |
| 2019-05-23 | Fortgesetzt | Goldman | Neutral |
| 2019-04-12 | Eingeleitet | Evercore ISI | Outperform |
| 2019-03-06 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2019-03-05 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2019-01-23 | Eingeleitet | UBS | Neutral |
| 2018-10-01 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2018-08-13 | Bestätigt | Stifel | Buy |
| 2018-08-07 | Hochstufung | Stifel | Hold → Buy |
| 2018-05-04 | Bestätigt | Stifel | Hold |
| 2018-03-28 | Eingeleitet | Evercore ISI | In-line |
Alle ansehen
Alnylam Pharmaceuticals Inc Aktie (ALNY) Neueste Nachrichten
Alnylam (ALNY) and Seagate (STX) Join Nasdaq 100 Index - GuruFocus
Lululemon, Biogen to exit Nasdaq 100 with Alnylam, Seagate among additions - MSN
Seagate, Alnylam Are Among Six Companies Set to Join Nasdaq 100 - Bloomberg.com
Annual Changes to the Nasdaq-100 Index® - GlobeNewswire Inc.
Implied Volatility Surging for Alnylam Pharmaceuticals Stock Options - Yahoo Finance
Is It Too Late to Consider Alnylam Pharmaceuticals After Its Huge 2025 Share Price Surge? - simplywall.st
Alnylam Announces Partial Repurchase of 1.00% Convertible Senior Notes Due 2027 - BioSpace
Is Alnylam Pharmaceuticals Stock Built to Withstand More Downside? - Trefis
$73 Billion Non-Opioid Therapeutics Industry Assessment, - GlobeNewswire
$73 Billion Non-Opioid Therapeutics Industry Assessment, 2032 Featuring AbbVie, GlaxoSmithKline, Acorda Therapeutics, Allay Therapeutics, Alnylam Pharmaceuticals and Other Key Players - Yahoo Finance
Alnylam (ALNY) Announces $34.4M Convertible Notes Repurchase - GuruFocus
Alnylam Pharmaceuticals stock price target raised by Stifel to $508 - Investing.com
ALNY: Stifel Raises Price Target to $508, Maintains Buy Rating | ALNY Stock News - GuruFocus
Alnylam to repurchase $34.4 million of convertible notes - Investing.com
Alnylam Pharma Announces Convertible Notes Buyback - TipRanks
Alnylam Announces Partial Repurchase Of 1.00% Convertible Senior Notes Due 2027 - TradingView
Alnylam Pharmaceuticals, Inc. Announces Partial Repurchase of Convertible Notes - TradingView
United States Gene Therapy Market to Hit $6510.45 Million by 2033 - openPR.com
authID (NASDAQ: AUID) PrivacyKey named 2025 PayTech Awards Best Digital Trust Solution - Stock Titan
Thematics Asset Management Purchases New Shares in Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat
Alnylam Pharmaceuticals, Inc. $ALNY Shares Purchased by Investment Management Corp of Ontario - MarketBeat
California Public Employees Retirement System Purchases 10,100 Shares of Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat
Alnylam Pharmaceuticals (NASDAQ:ALNY) Trading Down 5.5%Here's Why - MarketBeat
Winslow Capital Management LLC Has $383.95 Million Stock Position in Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat
Are Investors Undervaluing Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) By 24%? - Yahoo Finance
How (ALNY) Movements Inform Risk Allocation Models - news.stocktradersdaily.com
First Trust Advisors LP Boosts Holdings in Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat
Is Alnylam Pharmaceuticals a Millionaire Maker? - Finviz
Is Alnylam Pharmaceuticals a millionaire maker? - MSN
Will Board Overhaul And CEO Stock Moves Reshape Alnylam Pharmaceuticals' (ALNY) RNAi Investment Narrative - simplywall.st
Mirabella Financial Services LLP Decreases Stake in Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat
Marshall Wace LLP Sells 30,359 Shares of Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat
Schroder Investment Management Group Reduces Position in Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat
How Alnylam Pharmaceuticals Inc. stock benefits from tech adoptionJuly 2025 Volume & AI Optimized Trade Strategies - Newser
How Alnylam Pharmaceuticals Inc. (DUL) stock reacts to fiscal policiesMarket Sentiment Review & Risk Controlled Daily Trade Plans - Newser
Dodge & Cox Cuts Stake in Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat
Is Alnylam Pharmaceuticals Inc. (DUL) stock a fit for income portfoliosInsider Buying & Short-Term Trading Alerts - Newser
Is Alnylam Pharmaceuticals Inc. (DUL) stock trading at attractive multiples2025 Market Sentiment & Community Driven Trade Alerts - Newser
Do Alnylam Pharmaceuticals’ (ALNY) Board Moves Quietly Reframe Its Management Incentives and Risk Profile? - Yahoo Finance
Can Alnylam Pharmaceuticals Inc. (DUL) stock sustain institutional flowsPrice Action & Risk Controlled Daily Trade Plans - Newser
Alnylam Pharmaceuticals (ALNY): Is the Stock’s Recent Surge Justified by Its Valuation? - simplywall.st
What hedge fund activity signals for Alnylam Pharmaceuticals Inc. stock2025 Market Trends & Weekly Watchlist for Hot Stocks - Newser
What dividend safety rating applies to Alnylam Pharmaceuticals Inc. (DUL) stockJuly 2025 WrapUp & Daily Profit Focused Stock Screening - Newser
Will Alnylam Pharmaceuticals Inc. stock benefit from commodity pricesPortfolio Performance Report & Stock Market Timing Techniques - Newser
Is Alnylam Pharmaceuticals Inc. (DUL) stock prepared for digital transition2025 Price Targets & Low Risk Entry Point Tips - Newser
1832 Asset Management L.P. Raises Position in Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat
Alnylam announces board changes, appoints Stuart Arbuckle as director By Investing.com - Investing.com Nigeria
Alnylam Pharmaceuticals Announces Changes to Board of Directors - PharmiWeb.com
Alnylam Pharmaceuticals announces changes to board of directors - marketscreener.com
Alnylam announces board changes, appoints Stuart Arbuckle as director - Investing.com
Panagora Asset Management Inc. Trims Position in Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat
Finanzdaten der Alnylam Pharmaceuticals Inc-Aktie (ALNY)
Umsatz
Nettogewinn
Free Cashflow
ENV
Alnylam Pharmaceuticals Inc-Aktie (ALNY) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Fitzgerald Kevin Joseph | CSO & EVP, Head of Research |
Nov 17 '25 |
Option Exercise |
119.13 |
8,161 |
972,220 |
33,392 |
| Fitzgerald Kevin Joseph | CSO & EVP, Head of Research |
Nov 17 '25 |
Sale |
452.18 |
12,128 |
5,483,990 |
21,264 |
1.30%
0.91%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):